Ustekinumab for the treatment of Crohn's disease: can it find its niche?

Therapeutic Advances in Gastroenterology
Ebby G SimonGordon W Moran

Abstract

Crohn's disease is an immune-mediated disease that results in panenteric chronic inflammation in genetically predisposed individuals exposed to an appropriate environment. The past two decades have witnessed the emergence of an important class of drugs known as anti-tumour necrosis factor (TNF) agents in the treatment of Crohn's disease. Unfortunately, the utility of these agents have been hampered by primary and secondary nonresponse in a significant proportion of patients. Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin (IL) 12 and 23, is a novel pharmacotherapy for this patient cohort that offers an out-of-class option. It is approved for use in psoriasis and psoriatic arthritis, and has now been evaluated in phase II trials for moderate-to-severe Crohn's disease. We here review the published literature and describe a potential clinical role for its use in this disease cohort.

References

Nov 1, 1995·The Journal of Experimental Medicine·M F NeurathW Strober
May 6, 1999·The New England Journal of Medicine·D H PresentS J van Deventer
Jun 6, 2002·Lancet·Stephen B HanauerUNKNOWN ACCENT I Study Group
Feb 27, 2004·The New England Journal of Medicine·Bruce E SandsSander J van Deventer
May 4, 2006·The Journal of Clinical Investigation·David YenDonna Rennick
Jun 20, 2006·Immunity·Casey T WeaverKenneth M Murphy
Aug 22, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Christoph BeckerMarkus F Neurath
Feb 9, 2007·The New England Journal of Medicine·Gerald G KruegerUNKNOWN CNTO 1275 Psoriasis Study Group
May 2, 2007·Annals of Internal Medicine·William J SandbornPaul F Pollack
Jul 20, 2007·The New England Journal of Medicine·William J SandbornUNKNOWN PRECISE 1 Study Investigators
Jul 20, 2007·The New England Journal of Medicine·Stefan SchreiberUNKNOWN PRECISE 2 Study Investigators
Apr 15, 2008·The Journal of Investigative Dermatology·Andrew Blauvelt
Aug 19, 2008·Gastroenterology·William J SandbornUNKNOWN Ustekinumab Crohn's Disease Study Group
Mar 3, 2009·American Journal of Human Genetics·Kai WangHakon Hakonarson
Sep 8, 2009·The Journal of Allergy and Clinical Immunology·Elysia M HollamsPatrick G Holt
Jan 15, 2010·The New England Journal of Medicine·Christopher E M GriffithsUNKNOWN ACCEPT Study Group
May 18, 2010·Current Opinion in Gastroenterology·Warren StroberStefan Fichtner-Feigl
Jun 12, 2010·Birth Defects Research. Part B, Developmental and Reproductive Toxicology·Pauline L MartinGeorge Treacy
Dec 3, 2010·Journal of Crohn's & Colitis·A DignassUNKNOWN European Crohn's and Colitis Organisation (ECCO)
Dec 25, 2010·Therapeutic Advances in Gastroenterology·Ellen J ScherlRyan U Warren
Mar 17, 2011·The American Journal of Gastroenterology·Alexander C FordPaul Moayyedi
Apr 28, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·L GuentherH L Sofen
Aug 17, 2011·Archives of Dermatology·Jae JungCaroline Mann
Oct 12, 2011·Inflammatory Bowel Diseases·Laura M EhmannAndreas Wollenberg
Jul 13, 2012·Alimentary Pharmacology & Therapeutics·P S A de SilvaA N Ananthakrishnan
Oct 19, 2012·The New England Journal of Medicine·William J SandbornUNKNOWN CERTIFI Study Group
Dec 6, 2012·Birth Defects Research. Part B, Developmental and Reproductive Toxicology·Brian P EnrightGuenter Blaich
Jan 11, 2013·The British Journal of Dermatology·K A PappUNKNOWN ACCEPT Investigators
May 4, 2013·Patient Preference and Adherence·Eric ToussirotDelphine Binda
Aug 24, 2013·The New England Journal of Medicine·William J SandbornUNKNOWN GEMINI 2 Study Group
Oct 18, 2013·JAMA Dermatology·Emily F StamellSteven R Cohen
Feb 28, 2014·Journal of Crohn's & Colitis·Yaeesh BadatDavid Laharie

❮ Previous
Next ❯

Citations

Sep 25, 2016·Microbes and Infection·Eoin P Cummins, Daniel Crean
Nov 8, 2016·Expert Opinion on Biological Therapy·Bram VerstocktMarc Ferrante
Jan 31, 2017·Expert Opinion on Biological Therapy·Simon Hirschmann, Markus F Neurath
Apr 4, 2017·Immunology and Allergy Clinics of North America·Santhosh KumarAnne-Marie Irani
Jan 28, 2017·Advances in Medical Sciences·Zbigniew KmiećTomasz Jerzy Ślebioda
Jan 11, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·John B Grigg, Gregory F Sonnenberg
Apr 17, 2019·Journal of Crohn's & Colitis·Claire LiefferinckxUNKNOWN Belgian Inflammatory Bowel Disease Research and Development Group [BIRD group]
May 21, 2016·Current Opinion in Gastroenterology·George Kolios
Apr 10, 2019·Cell Death & Disease·Boning ZengFeiyue Xing
May 11, 2019·Digestive Diseases and Sciences·Mirabella Zhao, Johan Burisch
Sep 22, 2016·The FEBS Journal·Özge Uluçkan, Erwin F Wagner
May 22, 2017·Drugs·Yvette N Lamb, Sean T Duggan
Oct 26, 2016·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Xinyang LiZhihua Ran
Mar 19, 2021·JGH Open : an Open Access Journal of Gastroenterology and Hepatology·Anna ViolaUNKNOWN “Sicilian Network for Inflammatory Bowel Disease (SN‐IBD)”
Apr 4, 2018·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Alessandro ArmuzziMarco Daperno

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Clinical Trials Mentioned

NCT01369329
NCT01369342
NCT01369355

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Related Papers

Expert Review of Clinical Immunology
Jay Wofford, Alan Menter
Clinical, Cosmetic and Investigational Dermatology
Marina PapoutsakiSergio Chimenti
© 2022 Meta ULC. All rights reserved